Litcius/Paper detail

Severe Acute Respiratory Syndrome Coronavirus 2 Adaptive Immunity in Nursing Home Residents Following a Third Dose of the Comirnaty Coronavirus Disease 2019 Vaccine

Estela Giménez, Eliseo Albert, João Zulaica, Ignacio Torres, Luciana Rusu, Alicia Rodríguez-Moreno, Javier S. Burgos, Salvador Peiró, Dolores Salas, Hermelinda Vanaclocha, Ramón Limón, María Jesús Alcaráz, José Sánchez–Payá, Javier Díez‐Domingo, Iñaki Comas, Fernando Gónzález‐Candelas, Ron Geller, David Navarro, Javier S. Burgos, R. Meneu de Guillerna, Luna H Vanaclocha, D. J. Burks, Andrés Cervantes, Iñaki Comas, Javier Díez‐Domingo, Salvador Peiró, Fernando Gónzález‐Candelas, Albiach C Ferrer, Ildefonso Hernández‐Aguado, Ramírez N Oliver, José Sánchez–Payá, Torres M Vento, Latorre E Zapater, David Navarro

2022Clinical Infectious Diseases26 citationsDOIOpen Access PDF

Abstract

A third Comirnaty vaccine dose increased severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain antibody levels (median, 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (me 22-fold), Delta, (median, 43-fold), and Omicron (median, 8-fold) variants, but had less impact on S-reactive T-cell immunity in nursing home residents.

Topics & Concepts

MedicineCoronavirusCoronavirus disease 2019 (COVID-19)ImmunitySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakBetacoronavirusRespiratory systemVirologyDiseaseImmunologyIntensive care medicineInfectious disease (medical specialty)Immune systemInternal medicineOutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 and Mental HealthCOVID-19 Clinical Research Studies